-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ms.
In her desperate moment, an immunotherapy trial appeared in front of her.
The trial called "ADAPTeR" that she participated in was carried out by the Francis Crick Institute and was mainly used to explore immunotherapy related to kidney cancer
With the aid of the ADAPTeR trial, researchers have an opportunity to understand the reason and help patients increase the sensitivity of treatment
After analyzing all levels of genes, viruses, and tumor microenvironment, they found that a special type of T cell surface receptor has an important relationship with whether an individual responds to immunotherapy
▲Study diagram (picture source: reference [2])
According to their observations, after the immune system perceives that these cells can attack tumors, the number of these cells will continue to rise
Research points out that perhaps by detecting the number of specific T cells and T cell receptors in a patient, doctors can guess whether the patient can benefit from immunotherapy
For patients who are about to use immunotherapy, doctors may be able to detect their T cell response in advance, increasing the possibility of effective treatment
Note: The original text has been deleted
Reference materials:
[1]New immunotherapy insights for kidney cancer.
[2] Lewis Au, Emine Hatipoglu et al, Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma, Cancer Cell.
